Compare CSWC & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSWC | NTLA |
|---|---|---|
| Founded | 1961 | 2014 |
| Country | United States | United States |
| Employees | 30 | N/A |
| Industry | Textiles | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | N/A | 2016 |
| Metric | CSWC | NTLA |
|---|---|---|
| Price | $22.03 | $12.86 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 20 |
| Target Price | ★ $23.50 | $20.45 |
| AVG Volume (30 Days) | 570.5K | ★ 3.9M |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | ★ 11.92% | N/A |
| EPS Growth | N/A | ★ 27.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,671,000.00 |
| Revenue This Year | $17.45 | N/A |
| Revenue Next Year | $10.26 | $62.75 |
| P/E Ratio | $12.65 | ★ N/A |
| Revenue Growth | N/A | ★ 16.92 |
| 52 Week Low | $17.47 | $5.90 |
| 52 Week High | $23.84 | $28.24 |
| Indicator | CSWC | NTLA |
|---|---|---|
| Relative Strength Index (RSI) | 49.47 | 48.99 |
| Support Level | $21.30 | $12.55 |
| Resistance Level | $23.19 | $14.61 |
| Average True Range (ATR) | 0.47 | 0.74 |
| MACD | 0.02 | -0.12 |
| Stochastic Oscillator | 75.44 | 50.96 |
Capital Southwest Corp is a U.S.-based investment company that specializes in providing customized financing to middle market companies across various industries. The company's investment objective is to produce attractive risk-adjusted returns by generating current income from debt investments and capital appreciation from equity and equity related investments. It focuses on providing flexible financing solutions through partnerships with business owners, management teams, and financial sponsors. The company's portfolio may include senior debt, second lien, and subordinated debt, preferred stocks, common stocks, and warrants. The primary source company's revenue comprises interest income and dividend income from investments made as well as management fees.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.